Work

Abstract B034: A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2)

Year: 2023

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-23-b034

Authors: Ecaterina E. Dumbrava, Christopher T. Chen, Gregory M. Cote, Glenn J. Hanna, Thomas E. Stinchcombe, Bradley Sumrall, Trisha Wise-Draper, Mohammed Kanaan, Steven Duffy, Christopher Sumey, Patrick Cobb, Naisargee Shah, Bo Zhang, Nora Ku, Robert C. Doebele, Mrinal Gounder

Institutions: The University of Texas MD Anderson Cancer Center, Stanford Medicine, Massachusetts General Hospital, Dana-Farber Cancer Institute, Duke Cancer Institute, Navicent Health, University of Cincinnati, University of Cincinnati Medical Center, Northwest Medical Specialties, Hematology Oncology Associates of Central New York, Sanford Health, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389227602

Cites:

Cited by: 1

Related to: 10